English German
 

Products & Pipeline

CytoTools is turning fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms.

Using this approach the Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics across a range of disease indications. For more details about each therapeutic, click on the relevant product name in the pipeline chart.

Product
Market
Pre-Clinical
Phase I
Indication
Phase II
Phase III
DermaPro®
Diabetic foot ulcer
India
Market approval received in March 2017

DermaPro® (CL05) is an innovative drug that is derived from dichloric acid. It is applied to poorly healing and chronic wounds by a moist wound dressing. This wound healing therapy addresses the large unmet medical need associated with difficult to heal wounds.

Read more

DermaPro®
Diabetic foot ulcer
Europe
Phase III (must be repeated)

DermaPro® (CL05) is an innovative drug that is derived from dichloric acid. It is applied to poorly healing and chronic wounds by a moist wound dressing. This wound healing therapy addresses the large unmet medical need associated with difficult to heal wounds.

Read more

DermaPro®
Venous leg ulcer
Europe
Phase II/III (must be repeated)

DermaPro® (CL05) is an innovative drug that is derived from dichloric acid. It is applied to poorly healing and chronic wounds by a moist wound dressing. This wound healing therapy addresses the large unmet medical need associated with difficult to heal wounds.

Read more

DermaPro®
Venous leg ulcer
USA
Phase III (postponed)

A clinical Phase 3 study is currently in preparation for US approval of DermaPro® in the ulcus cruris (venous leg ulcer=VLU) indication. A close liaison with FDA to agree the study design should facilitate the VLU study launch in first half of 2015.

DermaPro® Pep04
Burns
Phase I

DermaPro® Pep04 is a peptide-based active substance for the treatment of burns and large-area wounds. In the case of these wounds a defect in connective tissue growth exists.

Read more

CardioClean® (HMW 02Ap/Ak)
Restenosis, diabetis, carotis-stenosis
Pre-Clinical

HMW 02Ap/Ak is currently in preclinical development, primarily for the treatment of restenosis and carotid stenosis (occlusion of blood vessels).

Read more

LMW 0x
Arteriosclerosis
R & D

LMW 0x is a further development of the drug HMW02. It is characterized by better bioavailability and can be taken orally. This low molecular weight substance is to be used for the treatment of arteriosclerosis.

HMW 02Ac
Diagnostic
R & D

HMW 02Ac is developed in parallel to the active ingredients of the HMW series and should act as a powerful diagnostic system to detect a nearly onset of arteriosclerotic changes. This way the treatment of arteriosclerosis can start earlier than with current diagnostic means.

Utisept®
Urinary tract infections
Medical Product

Utisept® is an urological medical device for flushing the bladder in urinary tract infections. It consists of an applicator that is used in combination with the Utisept ® disinfecting rinsing solution to quickly and effectively reduce a high initial bacterial load in the infected bladder (cystitis).

Read more